Initial Efficacy Data For GlycoMimetics, Inc.’ GMI-1271 Combined With Chemotherapy In Patients With AML To Be Presented At European Hematology Association 21st Congress

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the European Hematology Association’s 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
MORE ON THIS TOPIC